⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616675 | 0.83 | DGAT1 (0.37) | — | |
| SCHEMBL17553324 | 0.81 | GRM2 (0.32) | — | |
| SCHEMBL22586970 | 0.79 | — | — | |
| SCHEMBL22708204 | 0.74 | CHRM2 (0.38) | — | |
| SCHEMBL25131157 | 0.73 | CYP17A1 (0.40) | — | |
| SCHEMBL19966632 | 0.70 | — | — | |
| SCHEMBL23660727 | 0.69 | GLS (0.33) | — | |
| SCHEMBL25021669 | 0.69 | NPC1 (0.34) | — | |
| SCHEMBL25368727 | 0.69 | DGAT1 (0.41) | — | |
| SCHEMBL29493823 | 0.69 | DGAT1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210230170-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20200308170-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-10-01 | — | — | US | disclosed |
| US-20200262837-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-08-20 | — | — | US | disclosed |
| US-10689377-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |